The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study
Open accessAbstract
Parkinson plus diseases, comprising mainly progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) are rare neurodegenerative conditions. We designed a double-blind randomized placebo-controlled trial of riluzole as a potential disease-modifying agent in Parkinson plus disorders (NNIPPS: Neuroprotection and Natural History in Parkinson Plus Syndromes). We analysed the accuracy of our clinical diagnostic criteria, and studied prognostic factors for survival. Patients with an akinetic-rigid syndrome diagnosed as having PSP or MSA according to modified consensus diagnostic criteria were considered for inclusion. The psychometric validity (convergent and predictive) of the NNIPPS diagnostic criteria were tested prospectively by clinical and pathological assessments. The study was powered to detect a 40% decrease in relative risk of death within PSP or MSA strata. Patients were randomized to riluzole or matched placebo daily and followed up to 36 months. The primary endpoint was survival. Secondary efficacy outcomes were rates of disease progression assessed by functional measures. A total of 767 patients were randomized and 760 qualified for the Intent to Treat (ITT) analysis, stratified at entry as PSP (362 patients) or MSA (398 patients). Median follow-up was 1095 days (range 249-1095). During the study, 342 patients died and 112 brains were examined for pathology. NNIPPS diagnostic criteria showed for both PSP and MSA excellent convergent validity with the investigators' assessment of diagnostic probability (point-biserial correlation: MSA r(pb) = 0.93, P < 0.0001; PSP, r(pb) = 0.95, P < 0.0001), and excellent predictive validity against histopathology [sensitivity and specificity (95% CI) for PSP 0.95 (0.88-0.98) and 0.84 (0.77-0.87); and for MSA 0.96 (0.88-0.99) and 0.91 (0.86-0.93)]. There was no evidence of a drug effect on survival in the PSP or MSA strata (3 year Kaplan-Meier estimates PSP-riluzole: 0.51, PSP-placebo: 0.50; MSA-riluzole: 0.53, MSA-placebo: 0.58; P = 0.66 and P = 0.48 by the log-rank test, respectively), or in the population as a whole (P = 0.42, by the stratified-log-rank test). Likewise, rate of progression was similar in both treatment groups. There were no unexpected adverse effects of riluzole, and no significant safety concerns. Riluzole did not have a significant effect on survival or rate of functional deterioration in PSP or MSA, although the study reached over 80% power to detect the hypothesized drug effect within strata. The NNIPPS diagnostic criteria were consistent and valid. They can be used to distinguish between PSP and MSA with high accuracy, and should facilitate research into these conditions relatively early in their evolution.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Health Measurement Scales: A Practical Guide to Their Development and Use
Streiner, D. L., Norman, G. R., & Cairney, J. (1989) · Cited by 9,595
Discrete Multivariate Analysis: Theory and Practice.
Beniger, J. R., Bishop, Y. M. M., Feinberg, S. E., Holland, P. W., Light, R. J., & Mosteller, F. (1975) · Contemporary Sociology · doi:10.2307/2063625 · Cited by 5,108
Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538
Self-citationSurvival analysis using the SAS system : a practical guide
Allison, P. D. (1995) · Medical Entomology and Zoology · Cited by 2,402
A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
Bensimon, G., Lacomblez, L., & Meininger, V. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300901 · Cited by 2,233
Self-citationHealth Measurement Scales: A Practical Guide To Their Development And Use
Streiner, D. L., & Norman, G. R. (2003) · doi:10.1093/oso/9780198528470.001.0001 · Cited by 1,460
Consensus statement on the diagnosis of multiple system atrophy
Gilman, S., Low, P., Quinn, N., Albanese, A., Ben-Shlomo, Y., Fowler, C., Kaufmann, H., Klockgether, T., Lang, A., Lantos, P., et al. (1998) · Clinical Autonomic Research · doi:10.1007/bf02309628 · Cited by 1,308
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis/Riluzole Study Group II, Lacomblez, L., Bensimon, G., Meininger, V, Leigh, P. N., & Guillet, P. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91680-3 · Cited by 1,301
Self-citationRiluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, R. G., Mitchell, J. D., & Moore, D. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001447.pub3 · Cited by 1,058
SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders
Litvan, I., Bhatia, K. P., Burn, D. J., Goetz, C. G., Lang, A. E., McKeith, I., Quinn, N., Sethi, K. D., Shults, C., & Wenning, G. K. (2003) · Movement Disorders · doi:10.1002/mds.10459 · Cited by 1,009
Papp, M. I., Kahn, J. E., & Lantos, P. L. (1989) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(89)90219-0 · Cited by 991
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, R., Mitchell, J., Lyon, M., & Moore, D. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001447 · Cited by 909
Hauw, J.-J., Daniel, S. E., Dickson, D., Horoupian, D. S., Jellinger, K., Lantos, P. L., McKee, A., Tabaton, M., & Litvan, I. (1994) · Neurology · doi:10.1212/wnl.44.11.2015 · Cited by 852
The Role of Excitotoxicity in Neurodegenerative Disease
Doble, A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00042-4 · Cited by 723
Williams, D. R., de Silva, R., Paviour, D. C., Pittman, A., Watt, H. C., Kilford, L., Holton, J. L., Revesz, T., & Lees, A. J. (2005) · Brain · doi:10.1093/brain/awh488 · Cited by 667
Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study
Schrag, A., Ben-Shlomo, Y., & Quinn, N. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04137-9 · Cited by 642
A clinical rating scale for progressive supranuclear palsy
Golbe, L. I., & Ohman-Strickland, P. A. (2007) · Brain · doi:10.1093/brain/awm032 · Cited by 614
Progression and prognosis in multiple system atrophy
Watanabe, H., Saito, Y., Terao, S., Ando, T., Kachi, T., Mukai, E., Aiba, I., Abe, Y., Tamakoshi, A., Doyu, M., et al. (2002) · Brain · doi:10.1093/brain/awf117 · Cited by 598
Alternative excitotoxic hypotheses
Albin, R. L., & Greenamyre, J. T. (1992) · Neurology · doi:10.1212/wnl.42.4.733 · Cited by 574
The α‐Synucleinopathies: Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy
SPILLANTINI, M. G., & GOEDERT, M. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06900.x · Cited by 523
Mattson, M. P. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:3:2:65 · Cited by 475
Litvan, I., Hauw, J. J., Bartko, J. J., Lantos, P. L., Daniel, S. E., Horoupian, D. S., McKee, A., Dickson, D., Bancher, C., Tabaton, M., et al. (1996) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199601000-00010 · Cited by 475
Williams, D. R., Holton, J. L., Strand, C., Pittman, A., de Silva, R., Lees, A. J., & Revesz, T. (2007) · Brain · doi:10.1093/brain/awm104 · Cited by 417
Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration
Dickson, D. W. (1999) · Journal of Neurology · doi:10.1007/bf03161076 · Cited by 416
Litvan, I., Mangone, C. A., McKee, A., Verny, M., Parsa, A., Jellinger, K., D'Olhaberriague, L., Chaudhuri, K. R., & Pearce, R. K. (1996) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.60.6.615 · Cited by 410
Bower, J. H., Maraganore, D. M., McDonnell, S. K., & Rocca, W. A. (1997) · Neurology · doi:10.1212/wnl.49.5.1284 · Cited by 399
Litvan, I., Agid, Y., Jankovic, J., Goetz, C., Brandel, J. P., Lai, E. C., Wenning, G., D'Olhaberriague, L., Verny, M., Chaudhuri, K. R., et al. (1996) · Neurology · doi:10.1212/wnl.46.4.922 · Cited by 350
Self-citationProgressive Supranuclear Palsy: Pathology and Genetics
Dickson, D. W., Rademakers, R., & Hutton, M. L. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00054.x · Cited by 314
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, R. G., Mitchell, J. D., Lyon, M., & Moore, D. H. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001447.pub2 · Cited by 313
Prevalence and natural history of progressive supranuclear palsy
Golbe, L. I., Davis, P. H., Schoenberg, B. S., & Duvoisin, R. C. (1988) · Neurology · doi:10.1212/wnl.38.7.1031 · Cited by 309
Clinical features and natural history of progressive supranuclear palsy: A clinical cohort study
Nath, U., Ben-Shlomo, Y., Thomson, R. G., Lees, A. J., & Burn, D. J. (2003) · Neurology · doi:10.1212/01.wnl.0000052991.70149.68 · Cited by 281
Robbins, T. W., James, M., Owen, A. M., Lange, K. W., Lees, A. J., Leigh, P. N., Marsden, C. D., Quinn, N. P., & Summers, B. A. (1994) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.1.79 · Cited by 272
Self-citationThe prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK
Nath, U. (2001) · Brain · doi:10.1093/brain/124.7.1438 · Cited by 252
Correlation of dopamine transporter imaging with parkinsonian motor handicap: How close is it?
Pirker, W. (2003) · Movement Disorders · doi:10.1002/mds.10579 · Cited by 232
Litvan, I. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550200007003 · Cited by 213
Heiser, V., Engemann, S., Bröcker, W., Dunkel, I., Boeddrich, A., Waelter, S., Nordhoff, E., Lurz, R., Schugardt, N., Rautenberg, S., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182426599 · Cited by 205
Consensus guidelines for the design and implementation of clinical trials in ALS
Miller, R. G., Munsat, T. L., Swash, M., & Brooks, B. R. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00209-9 · Cited by 187
Pathogenesis of nigral cell death in Parkinson's disease
Przedborski, S. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.10.012 · Cited by 183
Accuracy of clinical diagnosis of progressive supranuclear palsy
Osaki, Y., Ben‐Shlomo, Y., Lees, A. J., Daniel, S. E., Colosimo, C., Wenning, G., & Quinn, N. (2004) · Movement Disorders · doi:10.1002/mds.10680 · Cited by 183
Riluzole in Huntington's disease: a 3‐year, randomized controlled study
Landwehrmeyer, G. B., Dubois, B., de Yébenes, J. G., Kremer, B., Gaus, W., Kraus, P. H., Przuntek, H., Dib, M., Doble, A., Fischer, W., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21181 · Cited by 176
Self-citationBensimon, G., Lacomblez, L., Delumeau, J. C., Bejuit, R., Truffinet, P., & Meininger, V. (2002) · Journal of Neurology · doi:10.1007/s004150200071 · Cited by 172
Self-citationAttia, J. (2003) · Australian Prescriber · doi:10.18773/austprescr.2003.082 · Cited by 166
Analysing changes in the presence of informative right censoring caused by death and withdrawal
Wu, M. C., & Bailey, K. (1988) · Statistics in Medicine · doi:10.1002/sim.4780070134 · Cited by 158
COGNITIVE PERFORMANCE IN MULTIPLE SYSTEM ATROPHY
Robbins, T. W., James-Galton, M., Lange, K. W., Owen, A. M., Quinn, N. P., & MARSDEN, C. D. (1992) · Brain · doi:10.1093/brain/115.1.271 · Cited by 150
Cellular pathology of multiple system atrophy: a review.
Lantos, P. L., & Papp, M. I. (1994) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.2.129 · Cited by 144
Progressive supranuclear palsy: where are we now?
Burn, D. J., & Lees, A. J. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00161-8 · Cited by 139
Survival in multiple system atrophy
Schrag, A. E., Wenning, G. K., Quinn, N. P., & Ben‐Shlomo, Y. (2007) · Movement Disorders · doi:10.1002/mds.21839 · Cited by 130
Progressive supranuclear palsy: A survey of the disease course
Santacruz, P., Uttl, B., Litvan, I., & Grafman, J. H. (1998) · Neurology · doi:10.1212/wnl.50.6.1637 · Cited by 127
Do published criteria improve clinical diagnostic accuracy in multiple system atrophy?
Osaki, Y., Ben‐Shlomo, Y., Wenning, G. K., Daniel, S. E., Hughes, A., Lees, A. J., Mathias, C. J., & Quinn, N. P. (2002) · Neurology · doi:10.1212/01.wnl.0000028690.15001.00 · Cited by 125
Geser, F., Wenning, G., Seppi, K., Stampfer-Kountchev, M., Scherfler, C., Sawires, M., Frick, C., Ndayisaba, J., Ulmer, H., Pellecchia, M. T., et al. (2006) · Movement Disorders · doi:10.1002/mds.20678 · Cited by 122
Evolution of sporadic olivopontocerebellar atrophy into multiple system atrophy
Gilman, S., Little, R. J. A., Johanns, J. R., et al. (2000) · Neurology · doi:10.1212/wnl.55.4.527 · Cited by 112
Lyoo, C. H., Jeong, Y., Ryu, Y. H., Lee, S., Song, T., Lee, J. H., Rinne, J. O., & Lee, M. S. (2008) · Brain · doi:10.1093/brain/awm328 · Cited by 91
Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy
Testa, D., Monza, D., Ferrarini, M., Soliveri, P., Girotti, F., & Filippini, G. (2001) · Neurological Sciences · doi:10.1007/s100720100021 · Cited by 87
Cognitive function in multiple system atrophy of the cerebellar type
Bürk, K., Daum, I., & Rüb, U. (2006) · Movement Disorders · doi:10.1002/mds.20802 · Cited by 77
Update on epidemiological aspects of progressive supranuclear palsy
Litvan, I. (2003) · Movement Disorders · doi:10.1002/mds.10562 · Cited by 74
New insights into progressive supranuclear palsy
Albers, D. S., & Augood, S. J. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01794-x · Cited by 65
Epidemiology of multiple system atrophy
Vanacore, N., Bonifati, V., Fabbrini, G., Colosimo, C., Michele, G. D., Marconi, R., Nicholl, D. J., Locuratolo, N., Talarico, G., Romano, S., et al. (2001) · Neurological Sciences · doi:10.1007/s100720170064 · Cited by 59
Gilman, S., & Quinn, N. P. (1996) · Neurology · doi:10.1212/wnl.46.5.1197 · Cited by 46
Progressive supranuclear palsy
Rehman, H. U. (2000) · Postgraduate Medical Journal · doi:10.1136/pmj.76.896.333 · Cited by 39
Scherfler, C., Sather, T., Diguet, E., Stefanova, N., Puschban, Z., Tison, F., Poewe, W. H., & Wenning, G. K. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0245-5 · Cited by 37
Riluzole promotes cell survival and neurite outgrowth in rat sensory neuronesin vitro
Shortland, P. J., Leinster, V. H. L., White, W. K., & Robson, L. G. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05218.x · Cited by 35
Progressive Supranuclear Palsy
Litvan, I., & Lees, A. J. (2005) · Humana Press eBooks · doi:10.1385/1-59259-834-x:287 · Cited by 34
Epidemiology of progressive supranuclear palsy
Vanacore, N., Bonifati, V., Colosimo, C., et al. (2001) · Neurological Sciences · doi:10.1007/s100720170065 · Cited by 32
Diguet, E., Fernagut, P., Scherfler, C., Wenning, G. K., & Tison, F. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0206-z · Cited by 30
Clinical and Genetic Aspects of Progressive Supranuclear Palsy
Litvan, I., & Hutton, M. L. (1998) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879801100208 · Cited by 30
Caumont, A., Octave, J., & Hermans, E. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03711.x · Cited by 28
Clinical Trials in ALS: What Did We Learn from Recent Trials in Humans?
Meininger, V. (2005) · Neurodegenerative Diseases · doi:10.1159/000089627 · Cited by 22
The epidemiology of progressive supranuclear palsy (Steele–Richardson–Olszewski syndrome)
Nath, U., & Burn, D. J. (2000) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(00)00011-0 · Cited by 22
Cited by
Fanciulli, A., & Wenning, G. K. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1311488 · Cited by 809
The natural history of multiple system atrophy: a prospective European cohort study
Wenning, G. K., Geser, F., Krismer, F., Seppi, K., Duerr, S., Boesch, S., Köllensperger, M., Goebel, G., Pfeiffer, K. P., Barone, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70327-7 · Cited by 545
Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes
Coyle-Gilchrist, I. T. S., Dick, K. M., Patterson, K., Vázquez Rodríquez, P., Wehmann, E., Wilcox, A., Lansdall, C. J., Dawson, K. E., Wiggins, J., Mead, S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002638 · Cited by 540
Boxer, A. L., Yu, J.-T., Golbe, L. I., Litvan, I., Lang, A. E., & Höglinger, G. U. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30157-6 · Cited by 485
Priorities in Parkinson's disease research
Meissner, W. G., Frasier, M., Gasser, T., Goetz, C. G., Lozano, A., Piccini, P., Obeso, J. A., Rascol, O., Schapira, A., Voon, V., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3430 · Cited by 436
Metadata
- Authors
- Bensimon, G., Ludolph, A., Agid, Y., Vidailhet, M., Payan, C., & Leigh, P. N.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-11-23
- Volume
- 132
- Issue
- 1
- Pages
- 156-171
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2122211082
- Cited by
- 347
- References
- 73
- FWCI
- 9.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.